Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 173

Sort by

Sort Order Select

Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Blood (2023) 142 (Supplement 1): 5933.

https://doi.org/10.1182/blood-2023-179609

Published: 2023

Journal Articles

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Patrice Chevallier, Hongtao Liu, Gary J. Schiller, Jean-Baptiste Méar, Daniel J. DeAngelo, Kevin J Curran, Stephan Grupp, Andre Baruchel, Marie Balsat, Alexandra LaCroce, Caroline Roudet, Ana B. Korngold, Kathryn J. Newhall, Eric Laille, Daniel J. Lee, Mark G. Frattini, Richard A. Larson, Nicolas Boissel

Blood (2023) 142 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2023-187252

Published: 2023

Journal Articles

Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open Label Expanded Access Program

Mitchell Horwitz, Stephanie B. Tsai, Andrew R. Rezvani, Richard T Maziarz, Uri Goshen, Stuart Levy, Aurelie Schwarzbach, Roei D. Mazor, Patrick J. Stiff, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 6894.

https://doi.org/10.1182/blood-2023-181167

Published: 2023

Journal Articles

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL)

Marcello Rotta, Farhad Ravandi, Mitul Gandhi, Paul B. Koller, Gary J. Schiller, Courtney Follit, Mona Vimal, Stephan W. Morris, Sanchita Mourya, Thomas Butler, Eunice S. Wang

Blood (2023) 142 (Supplement 1): 1546.

https://doi.org/10.1182/blood-2023-182361

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2023-186636

Published: 2023

Journal Articles

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

Monteserrat Arnan, Anand Ashwin Patel, Jordi Esteve, Lawrence Morris, Gary J. Schiller, Ronan T. Swords, Juan M. Alonso-Dominguez, Laura C. Michaelis, Naval Daver, Luis A. Carvajal, Gordon Bray, Elizabeth Olek, Richard E. Cutler, Jorge F. DiMartino, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 5973.

https://doi.org/10.1182/blood-2023-178804

Published: 2023

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2023) 142 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2023-187383

Published: 2023

Journal Articles

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Pankit Vachhani, Tsewang Tashi, Gary J. Schiller, Stephanie Lee, Miguel Piris Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Cristina Papayannidis, Khalid Shoumariyeh, Rita Petroro, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2023-178885

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Gail J. Roboz, Laura E. Finn, Johnnie J. Orozco, Mohamed Hegazi, Avinash Desai, Mary Chen, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2023-178802

Published: 2023

Journal Articles

B-Lymphoblastic Leukemia Presenting with Eosinophilia: A Case Report and Review

David Shabsovich, Michael J. Maranzano, Jonathan Said, Nam Ku, Sheeja Pullarkat, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 6059.

https://doi.org/10.1182/blood-2023-181232

Published: 2023

Journal Articles

Reconsidering the Significance of Blast Cut-Offs in Differentiating between MDS and AML Biology

Helen Shang, Claire Daniel, Michael J. Maranzano, Sarah Stettner, Daria Louise Gaut, Sophie Carlson, Yash Motwani, Alexandra M. Klomhaus, Caspian H. Oliai, Gary J. Schiller, Wanxing Chai-Ho

Blood (2023) 142 (Supplement 1): 1884.

https://doi.org/10.1182/blood-2023-189790

Published: 2023

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Daria Gaut, Caspian Oliai, Steven Tsai, Chiung-Yu Huang, Joseph Tuscano, Herbert Eradat, Gary J. Schiller

Blood (2022) 140 (Supplement 1): 12735–12736.

https://doi.org/10.1182/blood-2022-157466

Published: 2022

Journal Articles

Real-World Safety and Health Care Resource Utilization Analysis of Venetoclax and Hypomethylating-Agent Treatment for AML in an Academic-Affiliated Urban Community Oncology Network

Sophie G Carlson, Jonathan Boiarsky, Claire E. Daniel, Daria Gaut, Catherine Cascavita, Christine Lam, Michael Doyel, Gary J. Schiller, Wanxing Chai-Ho

Blood (2022) 140 (Supplement 1): 13282–13284.

https://doi.org/10.1182/blood-2022-165447

Published: 2022

Journal Articles

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Naveen Pemmaraju, Krishna Gundabolu, Jack Snyder, Michael H Silverman, Geraldine Bardelli, Srdan Verstovsek, Gary J. Schiller

Blood (2022) 140 (Supplement 1): 6821–6822.

https://doi.org/10.1182/blood-2022-169852

Published: 2022

Journal Articles

Suppression of Multiple Myeloma Via Inhibition of EFNB2 Reverse Signaling

Joshua P. Sasine, Jennifer Dukov, Dana Tran, Heather A Himburg, Natalia Kozlova, Michelle Li, Jenny Kan, Mary Sehl, Gary J. Schiller, Ritchie Ho, Brijesh Singh, Bryanna Reinhardt, Peibin Yue, Christina Termini, Elena Pasquale, John P. Chute

Blood (2022) 140 (Supplement 1): 4251–4252.

https://doi.org/10.1182/blood-2022-165357

Published: 2022

NARROW

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open Label Expanded Access Program

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL)

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

B-Lymphoblastic Leukemia Presenting with Eosinophilia: A Case Report and Review

Reconsidering the Significance of Blast Cut-Offs in Differentiating between MDS and AML Biology

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Real-World Safety and Health Care Resource Utilization Analysis of Venetoclax and Hypomethylating-Agent Treatment for AML in an Academic-Affiliated Urban Community Oncology Network

A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Suppression of Multiple Myeloma Via Inhibition of EFNB2 Reverse Signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only